Table 4 Comparison of clinical and demographic data in MTX non-responders vs responders (n = 1356)
From: Assessing the risk of rapid radiographic progression in Hungarian rheumatoid arthritis patients
Parameter | MTX non-responders (n = 691) | MTX responders (n = 665) | p |
|---|---|---|---|
Age (years) | 52.99 ± 12.15 | 58.16 ± 13.98 | < 0.001 |
Female gender (%) | 84 | 86 | 0.365 |
Disease duration (years) | 8.17 ± 8.73 | 8.72 ± 8.92 | 0.292 |
RF positivity (%) | 76 | 75 | 0.442 |
RF absolute level (IU/ml) | 153.55 ± 203.52 | 123.89 ± 187.21 | 0.002 |
ACPA positivity (%) | 72 | 70 | 0.139 |
CRP level (mg/l) | 21.24 ± 25.73 | 14.00 ± 21.01 | < 0.001 |
DAS28 score | 5.99 ± 0.68 | 3.98 ± 1.61 | < 0.001 |
Swollen joint count (n) | 8.87 ± 4.98 | 4.01 ± 4.74 | < 0.001 |
Current MTX therapy (%) | 83 | 45 | < 0.001 |
MTX therapy ever (%) | 96 | 89 | < 0.001 |
current csDMARD therapy (other than MTX) (%) | 44 | 25 | < 0.001 |
csDMARD therapy ever (other than MTX) (%) | 82 | 71 | < 0.001 |
Presence of erosions (%) | 67 | 61 | 0.033 |
Current smoker (%) | 29 | 23 | 0.030 |
Risk of RRP (%) | 37.82 ± 6.64 | 15.25 ± 8.90 | < 0.001 |
Risk of RRP – if switched to (infliximab (%) | 6.54 ± 4.18 | 5.84 ± 2.00 | 0.408 |